Tan et al., 2020 - Google Patents
C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 earlyTan et al., 2020
View PDF- Document ID
- 11962734385276901349
- Author
- Tan C
- Huang Y
- Shi F
- Tan K
- Ma Q
- Chen Y
- Jiang X
- Li X
- Publication year
- Publication venue
- Journal of medical virology
External Links
Snippet
COVID‐19 has developed into a worldwide pandemic; early identification of severe illness is critical for controlling it and improving the prognosis of patients with limited medical resources. The present study aimed to analyze the characteristics of severe COVID‐19 and …
- 102000025380 C-Reactive Protein 0 title abstract description 43
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/30—Information retrieval; Database structures therefor; File system structures therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F9/00—Arrangements for programme control, e.g. control unit
- G06F9/06—Arrangements for programme control, e.g. control unit using stored programme, i.e. using internal store of processing equipment to receive and retain programme
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F21/00—Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tan et al. | C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early | |
Wu et al. | Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID‐19) | |
Wang et al. | Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study | |
Zheng et al. | The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study | |
Chen et al. | A diagnostic model for coronavirus disease 2019 (COVID-19) based on radiological semantic and clinical features: a multi-center study | |
Qian et al. | Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series | |
Zeng et al. | Predictive value of the neutrophil to lymphocyte ratio for disease deterioration and serious adverse outcomes in patients with COVID-19: a prospective cohort study | |
Berti et al. | The epidemiology of antineutrophil cytoplasmic autoantibody–associated vasculitis in Olmsted County, Minnesota: a twenty‐year US population–based study | |
Liu et al. | Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study | |
Sweeney et al. | A community approach to mortality prediction in sepsis via gene expression analysis | |
Chen et al. | Differences between COVID‐19 and suspected then confirmed SARS‐CoV‐2‐negative pneumonia: a retrospective study from a single center | |
Cardoso et al. | C-reactive protein prognostic accuracy in acute pancreatitis: timing of measurement and cutoff points | |
Pan et al. | Can routine laboratory tests discriminate SARS‐CoV‐2‐infected pneumonia from other causes of community‐acquired pneumonia? | |
Song et al. | Clinical course and risk factors of fatal adverse outcomes in COVID-19 patients in Korea: a nationwide retrospective cohort study | |
Shu et al. | Clinical characteristics of moderate COVID‐19 patients aggravation in Wuhan Stadium Cabin Hospital: A 571 cases of retrospective cohort study | |
Jacobs et al. | The pediatric sepsis biomarker risk model (PERSEVERE) biomarkers predict clinical deterioration and mortality in immunocompromised children evaluated for infection | |
Willette et al. | Using machine learning to predict COVID-19 infection and severity risk among 4510 aged adults: a UK Biobank cohort study | |
Nabavi et al. | Clinical features and disease severity in an Iranian population of inpatients with COVID-19 | |
Chen et al. | Mycoplasma pneumoniae infection prediction model for hospitalized community‐acquired pneumonia children | |
Ucciferri et al. | Parameters associated with diagnosis of COVID‐19 in emergency department | |
Hydes et al. | Can routine blood tests be modelled to detect advanced liver disease in the community: model derivation and validation using UK primary and secondary care data | |
Sardinha et al. | Risk factors associated with the severity of COVID-19 in a region of the Brazilian Amazon | |
Luo et al. | Clinical characteristics and outcomes of 2019 novel coronavirus disease patients presenting with initial gastrointestinal symptoms in Wuhan, China: A retrospective cohort study | |
Yasar et al. | Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH) | |
Polilli et al. | Monocyte Distribution Width as a predictor of community acquired sepsis in patients prospectively enrolled at the Emergency Department |